‘Epigenetic Engineering’ Gene Therapy From Epic Bio Shows Early Promise
Progress For Non-Cutting CRISPR Technology
Executive Summary
The San Francisco-based company has taken a step forward with proof of concept for its ‘switch on or switch off’ approach to gene regulation via non-cutting CRISPR molecules.
You may also be interested in...
Finance Watch: VC Mega-Rounds Make A Comeback In March
Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.
Verve Hits The Clinic With Gene-Edited Cholesterol-Lowering Drug
The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.
The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses
ChatGPT’s ability to perform sophisticated analysis and writing tasks has taken the world by storm, and now one developer has launched its own AI aimed at revolutionizing pharma’s business intelligence functions.